*These authors contributed equally to this work.
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Hepatobiliary Malignancies
You have full text access to this OnlineOpen article
Loss of phosphatase and tensin homolog enhances cell invasion and migration through aKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance†
Article first published online: 22 APR 2011
DOI: 10.1002/hep.24232
Copyright © 2011 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Sze, K. M.-F., Wong, K. L.-T., Chu, G. K.-Y., Lee, J. M.-F., Yau, T.-O. and Oi-Lin Ng, I. (2011), Loss of phosphatase and tensin homolog enhances cell invasion and migration through aKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology, 53: 1558–1569. doi: 10.1002/hep.24232
- †
Potential conflict of interest: Nothing to report.
- ‡
*These authors contributed equally to this work.
- §
Fax: (852)-2872-5197
Publication History
- Issue published online: 22 APR 2011
- Article first published online: 22 APR 2011
- Accepted manuscript online: 11 FEB 2011 09:42AM EST
- Manuscript Accepted: 25 JAN 2011
- Manuscript Received: 16 SEP 2010
Funded by
- Hong Kong Research Grants Council Collaborative Research Fund. Grant Numbers: HKU 1/06C, HKU 7/CRF/09)
REFERENCES
- 1, . Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008; 28: 160-174.
- 2. Treatment of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19: 129-145.
- 3, , . Tenets of PTEN tumor suppression. Cell 2008; 133: 403-414.
- 4, , , , , , et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003; 97: 1929-1940.
- 5, , . Expression and significance of new tumor suppressor gene PTEN in primary liver cancer. J Cell Mol Med 2003; 7: 67-71.
- 6, , , , , , et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999; 18: 3181-3185.
- 7, , , . Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006; 25: 7009-7018.
- 8, , . Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004; 18: 1123-1125.
- 9, , , . The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. Int J Cancer 2007; 120: 1208-1214.
- 10, , , , , , et al. Establishment of cell lines from a primary hepatocellular carcinoma and its metastatis. Cancer Genet Cytogenet 2004; 148: 80-84.
- 11, , . beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001; 92: 136-145.
- 12, , , , , , et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997; 405: 157-162.
- 13, , . The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999; 274: 29130-29137.
- 14, , , , , , et al. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 2004; 15: 4841-4853.
- 15, , . Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Exp Cell Res 2009; 315: 2505-2514.
- 16, , , , , , et al. Regulation of PTEN by Rho small GTPases. Nat Cell Biol 2005; 7: 399-404.
- 17, , , , , . MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658.
- 18, , , , , , et al. Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1. Nat Cell Biol 2007; 9: 36-44.
- 19, , , , . ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 2010; 115: 1785-1796.
- 20, , , , , , et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82: 21-29.
- 21, , , . Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett 2010; 288: 156-161.
- 22, , . PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry 2009; 48: 1838-1846.
- 23, , , , , , et al. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 2006; 66: 4991-4995.
- 24, , . Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia 2007; 9: 406-417.
- 25, , , , , . Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney. Am J Physiol Renal Physiol 2003; 284: F82-F94.
- 26, , , , , , et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 2009; 39: 177-186.
- 27, , , , , , et al. The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol 2003; 129: 100-106.
- 28, , , , , . Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues. World J Gastroenterol 2007; 13: 4554-4559.
- 29, , . Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91: 1922-1932.
- 30, . Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 2003; 301: 50-53.
- 31, , , , , . Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001; 11: 764-768.
- 32, , , , , . PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther 2006; 5: 1008-1014.